Media coverage about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AEterna Zentaris earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.5039626980116 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern’s rankings:

AEZS has been the subject of a number of recent research reports. Maxim Group set a $4.00 target price on shares of AEterna Zentaris and gave the stock a “buy” rating in a report on Tuesday, November 28th. ValuEngine upgraded shares of AEterna Zentaris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, HC Wainwright set a $3.00 target price on shares of AEterna Zentaris and gave the stock a “buy” rating in a report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. AEterna Zentaris presently has an average rating of “Hold” and an average target price of $4.33.

Shares of AEterna Zentaris (AEZS) traded down $0.01 during trading on Wednesday, reaching $2.02. 337,700 shares of the company’s stock were exchanged, compared to its average volume of 1,004,056. AEterna Zentaris has a fifty-two week low of $0.78 and a fifty-two week high of $4.25.

ILLEGAL ACTIVITY WARNING: “AEterna Zentaris (AEZS) Receives Daily Coverage Optimism Rating of 0.17” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/20/aeterna-zentaris-aezs-receives-daily-coverage-optimism-rating-of-0-17.html.

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Insider Buying and Selling by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.